Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

28.61 -2.23 (-7.25%)
Streaming Delayed Price Updated: 11:08 AM EDT, Jul 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
News headline image
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease ↗
Beam Therapeutics shared updated BEAM-302 trial data in AATD and plans U.S. site activation following FDA clearance of its IND 
Via Benzinga
News headline image
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
From Beam Therapeutics
Via GlobeNewswire
News headline image
Analyst Expectations For Beam Therapeutics's Future ↗
 
Via Benzinga
News headline image
(BEAM) - Analyzing Beam Therapeutics's Short Interest ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox ↗
 
Via Benzinga
News headline image
Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed' ↗
 
Via Benzinga
News headline image
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock ↗
 
Via Benzinga
News headline image
Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
From Beam Therapeutics
Via GlobeNewswire
News headline image
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen ↗
Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV. 
Via Benzinga
News headline image
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity ↗
Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects. 
Via Benzinga
News headline image
Beam Therapeutics Announces Pricing of Underwritten Offering
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
From Beam Therapeutics
Via GlobeNewswire
News headline image
Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14% ↗
 
Via Benzinga
News headline image
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
News headline image
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday ↗
Cathie Wood-led Ark Invest made trades involving IRDM, TWST, PD, BEAM, ROKU, and IBTA. 
Via Benzinga
News headline image
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
From Beam Therapeutics
Via GlobeNewswire
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily
News headline image
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains ↗
Beam Therapeutics unveiled BEAM-101 trial data at ASH, showing improved outcomes in sickle cell patients and promising preclinical BEAM-103 results. 
Via Benzinga
News headline image
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.